Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Xencor (XE9) Stock Price & Analysis

0 Followers

XE9 Stock Chart & Stats

€32.20€1.40(4.55%)
At close: 5:30 PM GMT+1
€22€24€26Aug 20Oct 6Oct 26
Day’s Range
EUR 30.20 - EUR 32.20
52-Week Range
EUR 8.70 - EUR 32.20
Previous Close
EUR 30.80
Volume
N/A
Average Volume (3M)
7
Market Cap
EUR 2.39B
Enterprise Value
EUR 1.71B
Total Cash (Recent Filing)
EUR 405.08M
Total Debt (Recent Filing)
EUR 160.23M
Price to Earnings (P/E)
―
Beta
0.55
Next Earnings
Feb 24, 2027 (Est.)
EPS Estimate
-0.7
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong TTM Revenue Growth

The sharp increase in trailing revenue indicates meaningful commercial and collaboration activity across the business. Although Xencor remains clinical-stage, stronger top-line performance can support continued platform investment and improve the company’s ability to advance several programs over the next few quarters.

Manageable Leverage

A relatively modest debt burden gives Xencor greater financial flexibility than a heavily leveraged biotechnology company. The balance sheet can provide room to fund development programs and absorb operating volatility, while reducing the near-term pressure from mandatory debt service and refinancing needs.

Advancing XmAb819 Pipeline

XmAb819’s clinical progress and completed late-stage manufacturing preparation strengthen the visibility of Xencor’s lead solid-tumor program. Movement toward a potential registration-enabling study could create a more advanced development asset and expand the long-term value of the XmAb platform.

Bears Say

Substantial Cash Burn

Heavy operating and free-cash-flow losses show that Xencor is consuming cash rather than funding development internally. Persistent burn can reduce financial flexibility over time, increase reliance on external capital or partnership proceeds, and constrain the pace or breadth of pipeline investment.

Ongoing Operating Losses

Meaningful operating and net losses indicate that Xencor has not yet established sustainable earnings power. Continued unprofitability makes results more dependent on development milestones and other non-recurring revenue, while increasing the risk that future growth does not translate into durable shareholder returns.

Partner- And Milestone-dependent Revenue

Xencor’s revenue model depends heavily on partner decisions, contractual milestones, and the eventual commercial success of partnered products. That structure can create uneven financial results because revenue timing is linked to external clinical, regulatory, and commercial events rather than recurring product sales.

Xencor News

XE9 FAQ

What was Xencor’s price range in the past 12 months?
Xencor lowest stock price was €8.70 and its highest was €32.20 in the past 12 months.
What is Xencor’s market cap?
Xencor’s market cap is €2.39B.
When is Xencor’s upcoming earnings report date?
Xencor’s next earnings report is estimated for Feb 24, 2027 (not yet confirmed), which is in 106 days.
How were Xencor’s earnings last quarter?
Xencor released its earnings results on Nov 04, 2026. The company reported €0.446 earnings per share for the quarter, beating the consensus estimate of -€0.298 by €0.743.
Is Xencor overvalued?
According to Wall Street analysts Xencor’s price is currently Undervalued.
Does Xencor pay dividends?
Xencor does not currently pay dividends.
What is Xencor’s EPS estimate?
Xencor’s EPS estimate is -0.70.
How many shares outstanding does Xencor have?
Xencor has 75,039,690 shares outstanding.
What happened to Xencor’s price movement after its last earnings report?
Xencor reported an EPS of €0.446 in its last earnings report, beating expectations of -€0.298. Following the earnings report the stock price went up 14.925%.
Which hedge fund is a major shareholder of Xencor?
Hedge funds hold Xencor shares: the largest hedge-fund position in Xencor is 1,055,065,022 shares, and hedge funds increased their holdings by 227.8K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology